Literature DB >> 6285712

Use of acyclovir in premature and term neonates.

A S Yeager.   

Abstract

Nine infants with symptomatic infections caused by herpes simplex virus or cytomegalovirus were treated with acyclovir. At the onset of therapy, the infants ranged in weight from 880 to 4550 gm. Five were premature. Acyclovir was administered intravenously in a dosage of 5 to 15 mg/kg every eight hours for five to 10 days. The peak serum acyclovir levels ranged from 20 to 163 microM and the trough levels ranged from 1 to 129 microM. The variation in peak serum acyclovir levels in different infants receiving the same dosage on a weight basis was large but correlated with the expected renal maturity of the individual infant. Hematologic values improved during therapy. No renal toxicity was noted. All of the infants survived, including the five with herpes simplex infections.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285712     DOI: 10.1016/0002-9343(82)90092-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Antimicrobial therapy in newborn infants.

Authors:  M Bhat
Journal:  Indian J Pediatr       Date:  1983 Mar-Apr       Impact factor: 1.967

Review 2.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

3.  A case of neonatal herpes simplex with pneumonia.

Authors:  A N Campbell; M C O'Driscoll; D L Robinson; S E Read
Journal:  Can Med Assoc J       Date:  1983-10-01       Impact factor: 8.262

4.  Progressive calcifications of lung and liver in neonatal herpes simplex virus infection.

Authors:  W Mannhardt; R Schumacher
Journal:  Pediatr Radiol       Date:  1991

5.  Acycloguanosine therapy of the localized form of herpes simplex virus infection in a low-birth-weight infant.

Authors:  M Futamura; H Nagae; K Ishikawa; M Ouchi; M Kuroyanagi; T Morishima
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

Review 6.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

7.  Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial.

Authors:  L L Scott; L M Hollier; D McIntire; P J Sanchez; G L Jackson; G D Wendel
Journal:  Infect Dis Obstet Gynecol       Date:  2001

8.  Population pharmacokinetics of intravenous acyclovir in preterm and term infants.

Authors:  Mario R Sampson; Barry T Bloom; Robert W Lenfestey; Barrie Harper; Angela D Kashuba; Ravinder Anand; Daniel K Benjamin; Edmund Capparelli; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 3.806

9.  Acyclovir suppression to prevent recurrent genital herpes at delivery.

Authors:  L L Scott; L M Hollier; D McIntire; P J Sanchez; G L Jackson; G D Wendel
Journal:  Infect Dis Obstet Gynecol       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.